Clinical Trials Logo

Clinical Trial Summary

A web-based descriptive survey was conducted among doctors with regular interaction with gout patients. The questionnaire comprised of 38 multiple choice questions; 9 questions for demographic data, 8, 11 and 10 questions each for knowledge, attitude and practice, respectively. Simple descriptive statistics were used to describe the correct responses.


Clinical Trial Description

Objective To understand the knowledge, attitude and treatment practices of gout among doctors who regularly interacted with gout patients.

Methodology Study population: Physicians (including practicing medical graduates, post-graduates in internal medicine, family medicine) and orthopedic surgeons were selected randomly from the list of data from the Nepal Medical Council registry. All internists with valid email ID on the registry of the "society of internal medicine of Nepal" (SIMON) were included. Also, a list of MBBS graduates, family medicine and orthopedic practitioners working in the peripheral set-up of Nepal was obtained and a random selection with computer-generated random number table based on council registration number was made for enrollment into the survey. Estimating a response rate of 30%, a total of 1200 clinicians were selected based on their council registration number for the invitation to participate in the survey.

Survey instrument: A standardized questionnaire was designed by a 3-member committee of NRA focusing on the areas of knowledge, attitude and practice of gout with 9 questions pertaining to demographic parameters, 8 to knowledge about the disease, 11 to attitude and 10 to practice behaviors [tables 1-4]. The questions were designed as multiple-choice questions (MCQ) to be marked by the respondent. Few questions had the provision of selecting more than 1 options. Open- ended questions were avoided to save the time of the respondents and thus reduce the attrition rates[10].

Procedure: An email containing a letter of invitation for participation was sent to each of the selected participant. It mentioned why they were receiving the email, the objectives of the survey, the assurance of anonymity and confidentiality and a total answering time of less than 5 minutes for encouraging participation. A link to the Google-form was attached in the mail itself and a mention was made on the implied consent for participation in clicking the link. A reminder email was sent after 1 week to all irrespective of whether they had responded earlier.

Platform: A web-based platform was chosen with the use of Google-forms which was compatible and user friendly to both browser and mobile users and to both iOS and Android users. Multiple entries from the same email link were blocked. Web-based platform was chosen over email survey because it provides the ability to transfer survey responses directly into a database, eliminating transcription errors and preventing survey alteration by the survey respondent and most importantly maintaining confidentiality and anonymity of respondents[11]. The answers were collected anonymously in an excel sheet at the main server for analysis.

Statistical analysis: Simple descriptive statistics were used to describe the frequency or correct responses. Chi-square test was performed to assess the difference in knowledge, attitude, and practices between clinicians with different medical qualifications. Analysis was done using SPSS version 21 (SPSS, Inc., Chicago, IL, USA). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04519021
Study type Observational
Source National Center for Rheumatic Diseases, Nepal
Contact
Status Completed
Phase
Start date November 1, 2019
Completion date January 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Not yet recruiting NCT06187519 - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study N/A
Completed NCT03635957 - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Phase 4
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT03015948 - A Single Dose Study of SHR4640 in Healthy Male Volunteers Phase 1
Completed NCT02855437 - Novel Methods for Ascertainment of Gout Flares -A Pilot Study N/A
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00985127 - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT03291782 - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Phase 1
Recruiting NCT03388515 - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Enrolling by invitation NCT03336203 - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Phase 4
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Recruiting NCT04047394 - A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers Phase 1
Not yet recruiting NCT05507723 - Tight Control of Gouty Arthritis Compared to Usual Care N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2